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REVIEWStrengths and limitations of industry vs. academic randomized controlled
trialsP.-F. Laterre1 and B. François2
1) Department of Critical Care Medicine, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium and 2) Medical-Surgical Intensive Care
Unit, Limoges University Hospital, Limoges, FranceAbstractClinical research has evolved substantially over the last two decades, but industry-sponsored research is still substantially superior to
academic research in preparing, organizing and monitoring studies. Academics have to realize that conducting clinical research has
become a real job with professionalism requirements. The primary objectives of research and development clearly differ between
industry and academics. In the ﬁrst case, new drug development is expected to generate proﬁt, whereas in the latter case, research is
aimed at understanding mechanisms of disease, promoting evidence-based medicine, and improving public health and care. However, a
large number of clinical studies do not achieve their goals, and the reasons for failure may also differ between sponsored and academic
studies. Industry and academics should develop better constructive partnerships and learn from each other. Academics should guide
industry in study design and in investigator site selection, and academics should beneﬁt from industry’s expertise in improving monitoring
and reporting processes. Finally, the existing database from former studies should be opened and shared with academics, to enable the
exploration of additional scientiﬁc questions and the generation of new hypotheses. The two types of research should not be opposed,
but should take the form of a constructive collaboration, increasing the chances of reaching each individual goal.
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E-mail: pierre-francois.laterre@uclouvain.beIntroductionResearch driven by academics has often been considered to
have conﬂicts with industry. Pharmaceutical companies prob-
ably have the image of developing new compounds for proﬁt
only. Therefore, research and studies carried out by industry
are regularly criticized and perceived as potentially biased.
However, collaboration between industry and academics has
led to signiﬁcant advances in drug and technical developments.
Instead of opposing these two types of research, it would be
more proﬁtable to consider what can be learned from both
approaches and how this can improve new study design andMicrobiol Infect 2015; 21: 906–909
2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Soc
p://dx.doi.org/10.1016/j.cmi.2015.07.004developments for the beneﬁt of patients and healthcare. The
aims of this article are to review the beneﬁts and pitfalls of
academic and industry research, to provide some explanations
for the failure of studies, and to suggest some potential im-
provements for the future (Table 1).Primary objectives of industry and academic
researchIndustry is likely to develop new drugs or devices that are
expected to generate proﬁts for the company and share-
holders. After a new drug registration by the authorities, in-
dustry will perform further work on marketing strategies, to
increase sales and thereby increase the return on investment.
Companies may also develop new drugs for orphan disease
with an expected high sale price, on the assumption that the
healthcare system will often accept the charges, as it cannot beiety of Clinical Microbiology and Infectious Diseases
TABLE 1. Potential improvements for conducting academic
and industry research
Academic Industry
Improve study and ethics
committee submission
preparation
Study designed in collaboration with
actively involved academics
Improve data-monitoring
quality and learn from
the industry
Phase III trials not deﬁned by weak
phase II signals to meet marketing targets
Safety reporting not
restricted to
unexpected events
Site selection based on objective metrics
Knowledge of regulatory
authorities’ policies and
expectations
Redeﬁne a more realistic agenda and support
quality recruitment vs. volume
Study agenda to be better
established
Consider the use of a clinical coordinating centre
Multicentre rather than
single-centre studies
Access to study databank when completed
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care. On rare occasions, however, mainly because of public and
healthcare pressures, companies may provide ﬁnancial support
by reducing their sales margins for difﬁcult-to-access treat-
ments for low-income populations or countries, in order to
maintain a good public image.
Beneﬁts for academics, even though they are different from
those for industry, clearly exist. The career progression of
academics is driven by their scientiﬁc production and publica-
tion metrics. It is therefore not surprising that all efforts are
made by scientists to conduct studies aimed at rapid publica-
tion. This attitude may lead not only to the well-known data
cheating, but also to research of limited interest and beneﬁt for
the improvement of patient care [1]. It must be recognized that
some research and clinical studies have little relevance for a
better understanding of disease mechanisms. Also, some aca-
demics, when involved in sponsored studies, may pay more
attention to the expected impact of the subsequent associated
publications than to the value of the conducted research. The
publication policy of industry studies should often better
deﬁned before the conduct of a clinical trial, to more
adequately reward the actual investment of active investigators.Reasons for failure in academic and industry
researchStudy design and selected population
Despite the fact that the regulatory authorities are more likely
to approve a new drug if it has shown superiority to a
comparator used as part of the standard of care, numerous
companies have designed non-inferiority studies to access the
market. By evaluating the potential beneﬁt of their new com-
pound in a low-risk population, these trials were often unable
to detect some clinical cure failures or even inferiority as© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalfcompared with standard care. Numerous conﬁrmatory trials or
analyses of larger samples performed after market launching of
a new drug have demonstrated the limitations of the initial
studies that had resulted in its registration by the authorities
[2]. Academics are more likely to explore the possible efﬁcacy
of an intervention or a drug in a more severe group of patients
with comorbidities and a higher risk of death, without mar-
keting objectives, but targeting a population with important
unmet medical needs. Exploring antibiotic dosing regimens and
associated outcomes in the critically ill provides one example of
such academic studies. These studies have often supported the
need to consider the original label for the most severe patients
corresponding to a population for which more efforts should
be made [3]. However, industry cannot always be blamed for
this non-inferiority design approach. Indeed, recent examples of
new antibiotic approvals by regulatory authorities are ques-
tionable, and may have been facilitated by political consider-
ations, as the current era of bacterial multidrug resistance
represents a threat to the community [4].
The tight agenda of industry research
Industry has a well-deﬁned and tight agenda for a research plan.
Drug development takes years, and the patent-restricted period
after launching potentially limits the proﬁts that a company can
expect. Potential launching and marketing strategies have to be
established well in advance, when a promising drug is under early
development. Also, industry is responsible to shareholders, and
needs to complete its clinical studies within a very short period.
This agenda may signiﬁcantly impact on study quality, by resulting
in the enrolment of a suboptimal population. Indeed, industry is
often confronted by the problem of slower recruitment than
expected or not meeting the predeﬁned targets. Sponsors may
therefore potentially facilitate recruitment by unintentionally
opening the window to an inadequate patient population for the
initial primary objectives of the study, which is discovered later
when the database has been locked, and the part of the industry
team responsible for the trial has changed position in the com-
pany. Continuous monitoring of the enrolled population should
be systematically implemented, in order to more rapidly detect
inappropriate enrolments, and investigator sites should be
warned, or even closed, if a suboptimal patient population is
recruited on multiple occasions. Finally, the investigator fee and
ﬁnancial support offered by industry may bias the enrolment.
Indeed, the amount ofmoney provided by the sponsor per patient
included in a study may far exceed the actual personnel cost. The
associated positive balance may help an academic group in future
non-sponsored development, but may, on the other hand, in
some areas, directly beneﬁt the researcher. The high cost asso-
ciated with research and development has caused industry to
move in the direction of emerging markets [5]. In addition toof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 906–909
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have been conducted, the investigator’s fee offered for study
participation may, in some countries, exceed the physician’s
monthly salary, resulting in the enrolment rate being inappro-
priately enhanced, with an associated bias. Investigator contracts
should be systematically reviewed by an independent board from
the clinical institution, to prevent excessive unjustiﬁed fees.
Study site learning curve and clinical coordinating
centres
In large, multicentre, sponsored trials, an extensive study pro-
tocol description and a list of speciﬁc inclusion/exclusion
criteria are generally provided. However, numerous potentially
eligible patients may present with symptoms or conditions that
were not described or considered in the initial proposed pro-
tocol. The inclusion criteria may be too wide, and confounding
factors with a possible impact on the primary objective of a
study may have been omitted. Unfortunately, investigators too
often consider that they have sufﬁcient expertise to recognize
and select the most appropriate patients to enrol for a dedi-
cated study. This may be the cause of suboptimal population
enrolment in studies. It has also been demonstrated that the
ﬁrst patients enrolled within a single investigator centre have
more protocol violations regarding inclusion/exclusion criteria
or study drug administration than the subsequently included
patients [6]. Over time, a learning curve phenomenon has been
observed, and larger centres with higher recruitment, if
monitored, do provide more consistent enrolled populations.
Also, in order to meet the recruitment objectives, a sponsor
may decide to augment the number of study sites. This may
lead, based on the former observations, to a higher proportion
of inappropriate patients being recruited for the study, with an
associated impact on the ﬁnal primary objectives and study
results. Industry and academics should limit the number of
active sites for a dedicated study. Finally, in a recent publication,
it has been shown that some countries may be selected more
readily for participation in a study, because the study approval
process by local authorities or ethics committees may be
facilitated [7]. The centres should be selected according to their
size, infrastructure, capacity to enrol on a 24/7 base, and the
demonstration of their previous expertise in the ﬁeld with a
dedicated investigator team. In the vast majority of sponsored
studies, it has been observed that 10% of the sites recruit >50%
of the patients. Industry should collaborate with academics to
select centres for quality and consistency.
Industry studies: More favourable results and fewer
adverse events?
There is a general concern that industry research is biased, that
ﬁndings are false, and that study results are more often positive© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Socwhen the research is sponsored, even for non-inferiority trials
[8,9]. This raises the question of whether industry studies are
truly biased or better designed. Industry has, in general, strong
preclinical data, and may design trials that are more likely to
match with their primary objectives and marketing targets.
Academic single-centre phase II trials are less likely to lead to
positive phase III studies [10]. This may be explained by the
variability in the standard of care when multiple centres are
involved, but also by a different patient proﬁle for recruitment
in later developments or a centre effect in the initial phase II
trial.
A review of the literature supports the idea that industry
phase III trials are more likely to be positive than non-
sponsored studies. However, on review of some cancer
research conducted by industry as compared with academics,
the more pronounced beneﬁts observed initially in the former
also tended to occur in the latter [11]. This may be explained by
improvements achieved by academics in the way in which
research is structured and organized, and the way in which the
studied population is selected. In two recent publications, the
authors compared industry with academic studies in the ﬁeld of
statins, and demonstrated that the beneﬁts of the studied drugs
were observed in both types of study. The magnitude of
favourable effects was mostly driven by the compounds’
intrinsic properties, rather than the origin of the sponsorship
[12,13].
Data monitoring and reporting after drug market
launching
Industry has clearly demonstrated substantial superiority over
academics in the way that study protocols are submitted to the
regulatory authorities and how monitoring needs to be orga-
nized. In addition, for the vast majority of trials conducted by
industry, data collection is complete, and the entire process is
facilitated by the use of a contract research organization
(CRO). This process has, by deﬁnition, an associated cost that
academics are less likely to meet in order to achieve the same
objectives. However, because of the scope of data collection
combined with multiple associated queries, often suggested for
their own proﬁts by the CRO, the database closure is poten-
tially delayed, as is the ﬁnal study report. Academics, on their
side, have to learn from industry regarding the way to conduct
study preparation, ethics committee submission, and the quality
of data monitoring [14]. Despite a limited number of publica-
tions supporting the idea that academic studies are performing
adequately in the reporting process, it is generally admitted that
academic studies too often have much missing information,
together with restricted adverse event data collection [15]. This
is partially explained by the lack of sufﬁcient ﬁnancial resources,
but is probably too often secondary to limited experience ofiety of Clinical Microbiology and Infectious Diseases, CMI, 21, 906–909
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ever, sponsored research has been sometimes criticized for
minimizing some side effects described later when the drug has
been launched [16].ConclusionsThe restricted investments currently made by both industry
and public authorities in the ﬁeld of healthcare threaten future
research developments and possible improvements in the care
of patients for numerous diseases that are either not proﬁtable
for the former or have limited political impact for the latter.
Research conducted by industry should not be opposed to the
academic world developments, but these should be combined
for the beneﬁt of all. The ﬁnancial and organizational strengths
of industry should be shared with academics to enable the
better design, organization and performance of studies for the
beneﬁt of scientiﬁc knowledge and healthcare. Industry should
collaborate more with academics in the design of studies, the
deﬁnition of endpoints, and the selection of centres to perform
the research. The industry database should be accessible to and
shared with academics, to further explore additional questions
and raise new hypotheses. A recent report on the open access
provided by some companies is promising in this regard [17].
Also, the new initiative from the European Commission to
provide ﬁnancial support to academics and industry organized
in collaborative consortia to conduct studies for the develop-
ment of new diagnostic tools and drugs is promising. If this is
successful, both partners should achieve their respective goals
for the beneﬁt of patients and scientiﬁc developments.Transparency declarationPF L is a consultant at Ferring, Tigenix, Lascco and Versantis. B F
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